▼Ivabradine for stable angina?
- 5 November 2008
- journal article
- review article
- Published by BMJ in Drug and Therapeutics Bulletin
- Vol. 46 (11) , 84-88
Abstract
Up to 1 in 25 people in Europe and the USA have stable angina, with symptoms that may limit function and quality of life.1,2 Beta-blockers are usually used in initial symptomatic treatment, but may cause unwanted effects.3–6 They are also contraindicated in some patients (e.g. those with uncontrolled heart failure, severe peripheral vascular disease) and should be avoided in patients with asthma or a history of reversible obstructive airways disease or bronchospasm.6 ▼Ivabradine (Procoralan – Servier) is the first in a new class of specific heart rate-reducing drugs and is licensed for the “symptomatic treatment of chronic stable angina pectoris in patients with normal sinus rhythm, who have a contra-indication or intolerance for beta-blockers”.7,8 Here we consider the place of ivabradine in the management of patients with stable angina.Keywords
This publication has 10 references indexed in Scilit:
- Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trialThe Lancet, 2008
- Absence of respiratory effects with ivabradine in patients with asthmaBritish Journal of Clinical Pharmacology, 2008
- If Inhibition with IvabradineDrug Safety, 2008
- Ivabradine: a new strategy for management of stable anginaBritish Journal of Hospital Medicine, 2007
- Stable angina – who needs revascularisation?Drug and Therapeutics Bulletin, 2007
- Antianginal Efficacy and Safety of Ivabradine Compared with Amlodipine in Patients with Stable Effort Angina PectorisDrugs, 2007
- Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable anginaEuropean Heart Journal, 2005
- Antianginal and Antiischemic Effects of Ivabradine, an I f Inhibitor, in Stable AnginaCirculation, 2003
- The relationship between resting heart rate and all-cause, cardiovascular and cancer mortalityEuropean Heart Journal, 1997